[HTML][HTML] Precision medicine in breast cancer
Y Naito, T Urasaki - Chinese Clinical Oncology, 2018 - cco.amegroups.org
Precision medicine is a strategy for disease treatment and prevention that considers
individual variability in genes, environment, and lifestyle. Historically, breast cancer has been …
individual variability in genes, environment, and lifestyle. Historically, breast cancer has been …
[HTML][HTML] Clinicopathological and genomic features in patients with head and neck neuroendocrine carcinoma
…, Y Sato, R Asaka, N Fukuda, X Wang, T Urasaki… - Modern Pathology, 2021 - Elsevier
Neuroendocrine carcinoma (NEC) of the head and neck is a rare type of malignancy,
accounting for only 0.3% of all head and neck cancers, and its clinicopathological and genomic …
accounting for only 0.3% of all head and neck cancers, and its clinicopathological and genomic …
[HTML][HTML] Recent advances in medical therapy for urological cancers
T Yuasa, T Urasaki, R Oki - Frontiers in Oncology, 2022 - frontiersin.org
Currently, the paradigm of medical treatment for patients with metastatic urological cancer is
dramatically changing. Tyrosine kinase inhibitors, androgen deprivation therapy, and …
dramatically changing. Tyrosine kinase inhibitors, androgen deprivation therapy, and …
Sequential analysis of neutrophil-to-lymphocyte ratio for differentiated thyroid cancer patients treated with lenvatinib
N Fukuda, X Wang, A Ohmoto, T Urasaki, Y Sato… - in vivo, 2020 - iv.iiarjournals.org
Background/Aim: Neutrophil-to-lymphocyte ratio (NLR) has been reported to be associated
with poor prognosis for radioactive iodine ablation refractory differentiated thyroid cancer (RR…
with poor prognosis for radioactive iodine ablation refractory differentiated thyroid cancer (RR…
Efficacy of paclitaxel-based chemotherapy after progression on nivolumab for head and neck cancer
Y Sato, N Fukuda, YU Fujiwara, X Wang, T Urasaki… - in vivo, 2021 - iv.iiarjournals.org
Background/Aim: In the CheckMate-141 trial regarding head and neck cancer (HNC),
nivolumab conferred a survival benefit to patients. However, the best treatment sequence of …
nivolumab conferred a survival benefit to patients. However, the best treatment sequence of …
First‐in‐human study of E7130 (a tumor microenvironment‐ameliorating microtubule inhibitor) in patients with advanced solid tumors: Primary results of the dose …
…, Y Naito, Y Kuboki, K Harano, M Ono, T Urasaki… - Cancer, 2023 - Wiley Online Library
Background E7130 is a novel anticancer agent created from a total synthetic study of
norhalichondrin B. The authors report the E7130 dose‐escalation part of a first‐in‐human study of …
norhalichondrin B. The authors report the E7130 dose‐escalation part of a first‐in‐human study of …
Neutrophil-to-lymphocyte ratio as a prognostic marker for anaplastic thyroid cancer treated with lenvatinib
…, K Toda, YU Fujiwara, X Wang, A Ohmoto, T Urasaki… - in vivo, 2020 - iv.iiarjournals.org
Background/Aim: Lenvatinib is one of the few options for patients with anaplastic thyroid cancer
(ATC). However, tumor markers for ATC treated with lenvatinib is lacking. The aim of this …
(ATC). However, tumor markers for ATC treated with lenvatinib is lacking. The aim of this …
[HTML][HTML] Pre-treatment neutrophil-to-lymphocyte ratio (NLR) as a predictive marker of pazopanib treatment for soft-tissue sarcoma
Y Sato, K Nakano, X Wang, N Fukuda, T Urasaki… - Cancers, 2021 - mdpi.com
Simple Summary Second-line systematic therapy options for soft-tissue sarcoma (STS)
have remained unchanged for decades due to the rarity and various histological types …
have remained unchanged for decades due to the rarity and various histological types …
Mycophenolate mofetil as a successful treatment of corticosteroid-resistant immune checkpoint inhibitor-induced hepatitis
…, M Nishizawa, N Fukuda, T Urasaki… - Oxford Medical Case …, 2020 - academic.oup.com
Immune checkpoint inhibitors (ICIs) are now widely used to many malignant diseases, but
some patients suffer from immune-related adverse events during or after ICI treatments. The …
some patients suffer from immune-related adverse events during or after ICI treatments. The …
[HTML][HTML] Case report: a case of trimethoprim/sulfamethoxazole-triggered hypotensive shock: cytokine release syndrome related to immune checkpoint inhibitors and …
T Urasaki, M Ono, T Mochizuki, K Takeda… - Frontiers in …, 2021 - frontiersin.org
Currently, only a few reports exist on the cytokine release syndrome (CRS) as one of the
severe immune-related adverse events (irAEs) induced by immune checkpoint inhibitors (ICIs). …
severe immune-related adverse events (irAEs) induced by immune checkpoint inhibitors (ICIs). …